Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment-resistant depression. The company previously collected green lights for ...
ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain ...
ABBOTT PARK, Ill., May 16, 2023 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of ...
The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...
Abbott Laboratories is launching a clinical trial applying its deep brain stimulation system to a tough-to-treat form of depression. The company called its "Transcend" study a pivotal trial for ...
Abbott’s Infinity Deep Brain Stimulation (DBS) system has received an expanded clearance from the FDA that now permits the targeted stimulation of a new area of the brain associated with Parkinson’s ...
Abbott Laboratories (NYSE:ABT) received FDA approval to launch the Liberta RC DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people ...
Add MobiHealthNews to your network.
Please provide your email address to receive an email when new articles are posted on . The Proclaim DRG neurostimulation system aids in diagnosis and treatment of complex regional pain syndrome. The ...
The U.S. Food and Drug Administration and Abbott Laboratories were hit with a product liability lawsuit on Oct. 17 in Illinois Northern District Court over Abbott's Proclaim Elite spinal cord ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results